Overview Dividends

(JAZZ) Jazz Pharmaceuticals - Ratings and Ratios

Exchange: NASDAQ • Country: Ireland • Currency: USD • Type: Common Stock • ISIN: IE00B4Q5ZN47

Xywav, Xyrem, Epidiolex, Rylaze, Vyxeos

JAZZ EPS (Earnings per Share)

EPS Growth (3Y CAGR): 0.29%
EPS Trend (3Y Correlation): -45.6%

JAZZ Revenue

Revenue Growth (3Y CAGR): 3.93%
Revenue Trend (3Y Correlation): 44.5%

Description: JAZZ Jazz Pharmaceuticals November 06, 2025

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) is a Dublin-based specialty biopharma that develops and commercializes products across neurology, oncology, and hematology in the U.S., Europe, and other markets. Its approved portfolio includes Xywav and Xyrem for narcolepsy-related sleep disorders, Epidiolex for rare epilepsies, Rylaze/Enrylaze for acute lymphoblastic leukemia/lymphoblastic lymphoma, Zepzelca for small-cell lung cancer, Ziihera for HER-2 positive biliary tract cancers, Defitelio for veno-occlusive disease, and Vyxeos for therapy-related acute myeloid leukemia. The pipeline features late-stage assets such as Zanidatamab (Phase 3 HER-2 GEA), Suvecaltamide (Phase 2 Parkinson’s tremor), and several early-stage candidates targeting RAF kinase, interferon-alpha, and sleep disorders.

Key quantitative points (FY 2023): revenue of approximately $2.5 billion, with >55 % derived from specialty CNS and oncology products; R&D intensity around 15 % of sales, reflecting a focus on high-margin, niche indications; and a cash-and-equivalents position of roughly $1.2 billion, providing runway for upcoming trial readouts. Macro-level drivers include an aging population that expands demand for sleep-disorder therapies, continued growth in the global oncology market (projected CAGR ≈ 6 % through 2030), and favorable reimbursement trends for specialty drugs in the U.S.

For a deeper quantitative assessment, the ValueRay platform provides a granular breakdown of Jazz’s valuation metrics and scenario analysis.

JAZZ Stock Overview

Market Cap in USD	8,349m
Sub-Industry	Pharmaceuticals
IPO / Inception	2007-06-01

JAZZ Stock Ratings

Growth Rating	-19.5%
Fundamental	53.3%
Dividend Rating	-
Return 12m vs S&P 500	-3.40%
Analyst Rating	4.44 of 5

JAZZ Dividends

Currently no dividends paid

JAZZ Growth Ratios

Growth Correlation 3m	86.3%
Growth Correlation 12m	8.6%
Growth Correlation 5y	-75.2%
CAGR 5y	-4.23%
CAGR/Max DD 3y (Calmar Ratio)	-0.11
CAGR/Mean DD 3y (Pain Ratio)	-0.19
Sharpe Ratio 12m	1.22
Alpha	9.74
Beta	0.278
Volatility	29.66%
Current Volume	1041.8k
Average Volume 20d	560.3k
Stop Loss	127 (-3.2%)
Signal	1.01

Piotroski VR‑10 (Strict, 0-10) 6.0

Net Income (-404.8m TTM) > 0 and > 6% of Revenue (6% = 245.2m TTM)

FCFTA 0.12 (>2.0%) and ΔFCFTA 2.36pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 31.30% (prev 54.37%; Δ -23.06pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.12 (>3.0%) and CFO 1.32b > Net Income -404.8m (YES >=105%, WARN >=100%)

Net Debt (4.24b) to EBITDA (447.1m) ratio: 9.49 <= 3.0 (WARN <= 3.5)

Current Ratio 1.62 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (61.2m) change vs 12m ago -12.11% (target <= -2.0% for YES)

Gross Margin 88.71% (prev 85.52%; Δ 3.20pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 36.64% (prev 34.41%; Δ 2.23pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -1.07 (EBITDA TTM 447.1m / Interest Expense TTM 211.0m) >= 6 (WARN >= 3)

Altman Z'' 0.65

(A) 0.12 = (Total Current Assets 3.35b - Total Current Liabilities 2.07b) / Total Assets 10.94b

(B) 0.02 = Retained Earnings (Balance) 191.3m / Total Assets 10.94b

(D) -0.04 = Book Value of Equity -294.4m / Total Liabilities 7.24b

Total Rating: 0.65 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 53.33

1. Piotroski 6.0pt = 1.0

2. FCF Yield 10.44% = 5.0

3. FCF Margin 30.96% = 7.50

4. Debt/Equity 1.47 = 1.51

5. Debt/Ebitda 9.49 = -2.50

6. ROIC - WACC (= -6.85)% = -8.57

7. RoE -10.03% = -1.67

8. Rev. Trend 44.55% = 3.34

9. EPS Trend -45.62% = -2.28

What is the price of JAZZ shares?

As of November 08, 2025, the stock is trading at USD 131.16 with a total of 1,041,800 shares traded.
Over the past week, the price has changed by -4.71%, over one month by -4.49%, over three months by +17.02% and over the past year by +10.14%.

Is Jazz Pharmaceuticals a good stock to buy?

Neither. Based on ValueRay´s Fundamental Analyses, Jazz Pharmaceuticals is currently (November 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 53.33 and therefor a neutral outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of JAZZ is around 128.99 USD . This means that JAZZ is currently overvalued and has a potential downside of -1.65%.

Is JAZZ a buy, sell or hold?

Jazz Pharmaceuticals has received a consensus analysts rating of 4.44. Therefore, it is recommended to buy JAZZ.

Strong Buy: 10
Buy: 6
Hold: 2
Sell: 0
Strong Sell: 0

What are the forecasts/targets for the JAZZ price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	188.1	43.4%
Analysts Target Price	188.1	43.4%
ValueRay Target Price	138.8	5.8%

JAZZ Fundamental Data Overview November 03, 2025

Market Cap USD = 8.35b (8.35b USD * 1.0 USD.USD)
P/E Forward = 6.8966
P/S = 2.043
P/B = 2.2456
P/EG = 6.0482
Beta = 0.278
Revenue TTM = 4.09b USD
EBIT TTM = -225.4m USD
EBITDA TTM = 447.1m USD
Long Term Debt = 4.34b USD (from longTermDebt, last quarter)
Short Term Debt = 1.04b USD (from shortTermDebt, last quarter)
Debt = 5.43b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.24b USD (from netDebt column, last quarter)
Enterprise Value = 12.11b USD (8.35b + Debt 5.43b - CCE 1.67b)
Interest Coverage Ratio = -1.07 (Ebit TTM -225.4m / Interest Expense TTM 211.0m)
FCF Yield = 10.44% (FCF TTM 1.27b / Enterprise Value 12.11b)
FCF Margin = 30.96% (FCF TTM 1.27b / Revenue TTM 4.09b)
Net Margin = -9.91% (Net Income TTM -404.8m / Revenue TTM 4.09b)
Gross Margin = 88.71% ((Revenue TTM 4.09b - Cost of Revenue TTM 461.2m) / Revenue TTM)
Gross Margin QoQ = 88.88% (prev 88.35%)
Tobins Q-Ratio = 1.11 (Enterprise Value 12.11b / Total Assets 10.94b)
Interest Expense / Debt = 0.87% (Interest Expense 47.4m / Debt 5.43b)
Taxrate = 2.32% (-17.1m / -735.6m)
NOPAT = -220.2m (EBIT -225.4m * (1 - 2.32%)) [loss with tax shield]
Current Ratio = 1.62 (Total Current Assets 3.35b / Total Current Liabilities 2.07b)
Debt / Equity = 1.47 (Debt 5.43b / totalStockholderEquity, last quarter 3.71b)
Debt / EBITDA = 9.49 (Net Debt 4.24b / EBITDA 447.1m)
Debt / FCF = 3.35 (Net Debt 4.24b / FCF TTM 1.27b)
Total Stockholder Equity = 4.04b (last 4 quarters mean from totalStockholderEquity)
RoA = -3.70% (Net Income -404.8m / Total Assets 10.94b)
RoE = -10.03% (Net Income TTM -404.8m / Total Stockholder Equity 4.04b)
RoCE = -2.69% (EBIT -225.4m / Capital Employed (Equity 4.04b + L.T.Debt 4.34b))
RoIC = -2.25% (negative operating profit) (NOPAT -220.2m / Invested Capital 9.77b)
WACC = 4.60% (E(8.35b)/V(13.78b) * Re(7.04%) + D(5.43b)/V(13.78b) * Rd(0.87%) * (1-Tc(0.02)))
Discount Rate = 7.04% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -6.28%
[DCF Debug] Terminal Value 81.39% ; FCFE base≈1.18b ; Y1≈1.45b ; Y5≈2.46b
Fair Price DCF = 689.0 (DCF Value 41.80b / Shares Outstanding 60.7m; 5y FCF grow 24.66% → 3.0% )
EPS Correlation: -45.62 | EPS CAGR: 0.29% | SUE: -2.49 | # QB: 0
Revenue Correlation: 44.55 | Revenue CAGR: 3.93% | SUE: -0.04 | # QB: 0

Additional Sources for JAZZ Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle